🇺🇸 FDA
Pipeline program

Efgartigimod + Telitacicept (1-week interval) group

KY2024-298

Unknown small_molecule active

Quick answer

Efgartigimod + Telitacicept (1-week interval) group for Myasthenia Gravis is a Unknown program (small_molecule) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
First Tracks Biotherapeutics
Indication
Myasthenia Gravis
Phase
Unknown
Modality
small_molecule
Status
active

Clinical trials